Dexcom Launches the G7 with Apple Watch Integration
On June 5, 2024, Dexcom announced that its G7 continuous glucose monitor (CGM) now connects directly to the Apple Watch in the U.S.
Dexcom first revealed this implementation in March.
With its official release, the G7 becomes the first and only CGM with an Apple Watch direct-to-app function. Even without an iPhone nearby, it gives consumers the flexibility and convenience of real-time glucose readings.
Dexcom says this feature is also available in the UK and Ireland, and later this month it anticipates launching in more markets.
G7 uses its own dedicated Bluetooth connection to send glucose information and personalized alerts directly to an Apple Watch. This allows users to go for a run or enjoy social activities while feeling confident leaving their iPhone behind.
Previously, Dexcom users could view their glucose or blood sugar information on their Apple Watch screen, but they needed to be within Bluetooth-range of their iPhone (Dexcom says 33 feet) so the monitor could connect through the app.
G7 can now simultaneously and independently display glucose readings on multiple devices, including:
- Smartphones
- Smart watches
- Receivers or
- Connected automated insulin delivery systems.
Additionally, users can use Apple Watch’s built-in health functions to measure health variables that may have an impact on blood-sugar levels. Every piece of information is sent to the Health app, so customers can examine it all in one location with their G7 data.
“At Dexcom, our users are at the heart of everything we do. Direct to Apple Watch has been one of our most requested features, and we’re thrilled to roll it out to Dexcom G7 users in the U.S. and around the world,” said Jake Leach, executive vice president and chief operating officer at Dexcom. “We’ve long believed that people with diabetes should be able to view their CGM data where and how they choose. Direct to Apple Watch is a testament to that, allowing people with diabetes flexibility and choice in how they manage their health.”
News coverage by the Beyond Type 1 team is operated independently from any content partnerships.
Beyond Type 1 maintains full editorial control of all content published on our platforms.